These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33919737)

  • 1. New InhA Inhibitors Based on Expanded Triclosan and
    Chetty S; Armstrong T; Sharma Kharkwal S; Drewe WC; De Matteis CI; Evangelopoulos D; Bhakta S; Thomas NR
    Pharmaceuticals (Basel); 2021 Apr; 14(4):. PubMed ID: 33919737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Mycobacterium tuberculosis InhA: Design, synthesis and evaluation of new di-triclosan derivatives.
    Armstrong T; Lamont M; Lanne A; Alderwick LJ; Thomas NR
    Bioorg Med Chem; 2020 Nov; 28(22):115744. PubMed ID: 33007556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of isoniazid resistance-conferring mutations associated with multidrug-resistant tuberculosis in Free State Province, South Africa.
    Pitso L; Potgieter S; Van der Spoel van Dijk A
    S Afr Med J; 2019 Aug; 109(9):659-664. PubMed ID: 31635590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Prevalence of inhA Promoter Mutations among Patients with Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa.
    Niehaus AJ; Mlisana K; Gandhi NR; Mathema B; Brust JC
    PLoS One; 2015; 10(9):e0135003. PubMed ID: 26332235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid.
    Parikh SL; Xiao G; Tonge PJ
    Biochemistry; 2000 Jul; 39(26):7645-50. PubMed ID: 10869170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel diaryl ether derivatives as InhA inhibitors: Design, synthesis and antimycobacterial activity.
    Abdelaziz OA; Othman DIA; Abdel-Aziz MM; Badr SMI; Eisa HM
    Bioorg Chem; 2022 Dec; 129():106125. PubMed ID: 36126606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triclosan derivatives: towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis.
    Freundlich JS; Wang F; Vilchèze C; Gulten G; Langley R; Schiehser GA; Jacobus DP; Jacobs WR; Sacchettini JC
    ChemMedChem; 2009 Feb; 4(2):241-8. PubMed ID: 19130456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlating genetic mutations with isoniazid phenotypic levels of resistance in Mycobacterium tuberculosis isolates from patients with drug-resistant tuberculosis in a high burden setting.
    Pinhata JMW; Brandao AP; Mendes FF; Rabello MCDS; Ferrazoli L; de Oliveira RS
    Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2551-2561. PubMed ID: 34297229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triclosan and its derivatives as antimycobacterial active agents.
    Vosátka R; Krátký M; Vinšová J
    Eur J Pharm Sci; 2018 Mar; 114():318-331. PubMed ID: 29277667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of mutations associated with isoniazid resistance in multidrug-resistant Mycobacterium tuberculosis clinical isolates.
    Jagielski T; Bakuła Z; Roeske K; Kamiński M; Napiórkowska A; Augustynowicz-Kopeć E; Zwolska Z; Bielecki J
    J Antimicrob Chemother; 2014 Sep; 69(9):2369-75. PubMed ID: 24855126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of the coexistence of non-codon 315 katG, inhA, and oxyR-ahpC intergenic gene mutations among isoniazid-resistant and multidrug-resistant isolates of Mycobacterium tuberculosis: a report of novel mutations.
    Norouzi F; Moghim S; Farzaneh S; Fazeli H; Salehi M; Nasr Esfahani B
    Pathog Glob Health; 2022 Feb; 116(1):22-29. PubMed ID: 34086544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Discoveries of Nitrogen-Containing Heterocyclic Compounds as InhA Inhibitors against
    Gupta PD; Tilekar KN; Upadhyay NM; C S R
    Infect Disord Drug Targets; 2022; 22(8):19-29. PubMed ID: 35450533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress in the identification and development of InhA direct inhibitors of Mycobacterium tuberculosis.
    Lu XY; You QD; Chen YD
    Mini Rev Med Chem; 2010 Mar; 10(3):181-92. PubMed ID: 20408801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro Antimycobacterial Activity and Physicochemical Characterization of Diaryl Ether Triclosan Analogues as Potential InhA Reductase Inhibitors.
    Ibrahim TS; Taher ES; Samir E; M Malebari A; Khayyat AN; Mohamed MFA; Bokhtia RM; AlAwadh MA; Seliem IA; Asfour HZ; Alhakamy NA; Panda SS; Al-Mahmoudy AMM
    Molecules; 2020 Jul; 25(14):. PubMed ID: 32650556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First triclosan-based macrocyclic inhibitors of InhA enzyme.
    Rodriguez F; Saffon N; Sammartino JC; Degiacomi G; Pasca MR; Lherbet C
    Bioorg Chem; 2020 Jan; 95():103498. PubMed ID: 31855823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Advances and Structural Features of Enoyl-ACP Reductase Inhibitors of Mycobacterium tuberculosis.
    Inturi B; Pujar GV; Purohit MN
    Arch Pharm (Weinheim); 2016 Nov; 349(11):817-826. PubMed ID: 27775177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-Benzyl-4-((heteroaryl)methyl)benzamides: A New Class of Direct NADH-Dependent 2-trans Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors with Antitubercular Activity.
    Guardia A; Gulten G; Fernandez R; Gómez J; Wang F; Convery M; Blanco D; Martínez M; Pérez-Herrán E; Alonso M; Ortega F; Rullás J; Calvo D; Mata L; Young R; Sacchettini JC; Mendoza-Losana A; Remuiñán M; Ballell Pages L; Castro-Pichel J
    ChemMedChem; 2016 Apr; 11(7):687-701. PubMed ID: 26934341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis.
    Sullivan TJ; Truglio JJ; Boyne ME; Novichenok P; Zhang X; Stratton CF; Li HJ; Kaur T; Amin A; Johnson F; Slayden RA; Kisker C; Tonge PJ
    ACS Chem Biol; 2006 Feb; 1(1):43-53. PubMed ID: 17163639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotypic distribution of multidrug-resistant and extensively drug-resistant tuberculosis in northern Thailand.
    Jaksuwan R; Tharavichikul P; Patumanond J; Chuchottaworn C; Chanwong S; Smithtikarn S; Settakorn J
    Infect Drug Resist; 2017; 10():167-174. PubMed ID: 28706448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The first-in-class pyrazole-based dual InhA-VEGFR inhibitors towards integrated antitubercular host-directed therapy.
    Shaaban MM; Teleb M; Ragab HM; Singh M; Elwakil BH; A Heikal L; Sriram D; Mahran MA
    Bioorg Chem; 2024 Apr; 145():107179. PubMed ID: 38367430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.